BUY VERTEX PHARMACEUTICAL on reopeningHey traders,big upward effort it is possible to see an acceleration on this configuration, unless a change of decision takes place ...
Please LIKE & FOLLOW, thank you!
VRTX trade ideas
BUY VERTEX LONG TERM 285.05$May-11-20 04:31PM How A Gene-Editing Drug Sent This IBD Stock Of The Day To A New High Investor's Business Daily +5.03%
VRTX buy through all time high with solid earnings behind itWe started to see some consolidation after it had a good earnings reaction. 1st in its industry group with a A+ rating and accelerating earnings with price tightening up. The weekly looks good with a few weeks of consolidation
and 10 week MA just under that 275 low. I'll be looking for a buy for a half position through 276 against 267 and scale in my second half once its proves itself.
SHORT Short by put option to weekly level support $53SHORT Short by put option to weekly level support $53
$VRTX -- Similar to $LLY short pullback$VRTX has a very similar chart to $LLY can also short the pullback into an inverse as its sitting at its neckline.
Saham syarikat VRTXVRTX adalah kod bagi syarikat Vertex Pharmaceutical Inc yang diperbuat dari segi sektor kesihatan. Mengikut pemerhatian gelombang sahlun tentang saham ini adalah uptrend@bullish dengan kenaikkan sebanyak 5.92% dalam tempoh 3 bulan lepas. Dari segi Syariah, saham ini adalah Patuh Syariah
VRTX finds support at 240, double inverted head and shoulders.VRTX up after exceeding earnings on JAN 30, finds support at 240. 5 day moving average is strong. Double inverted head and shoulders signals strong buy, possible breakout. Entry at 243, target price 252, stop loss 241.
VRTX - DAILY CHART Hi, today we are going to talk about Vertex Pharmaceuticals and its current landscape.
Vertex Pharmaceuticals is poised to receive increasing attention from the market as relevant events are taking place after Proteostasis Therapeutics had unveiled "positive" data from a phase 2 clinical trial testing its triple-drug combination in patients with cystic fibrosis, however, the results were below than Vertex Pharmaceuticals similar product named Trikafta, giving Vertex an edge on the market, and possibly implying that the company could thrive over Proteostasis Therapeutics underperforming.
Thank you for reading and leave your comments if you like.
To have access to our exclusive contents, join the Traders Heaven today! Link Below.
Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
VRTX Swing ShortUsing a tight stop here with a wide target due to extended nature of this last impulse up and the fact that we're almost perfectly at the 1.618 extension of the last swing high -> swing low.
You can tighten your stop to directly above the highest wick of this impulse as well if you want to increase the Reward:Risk Ratio.
The other thing to watch is the Fibonacci node about 2.5% below this entry (around $215). This area is possible support and could snare price action in this small range for a while. If you're shorting the asset then you're fine but if you're buying puts you may want to cover when/if we reach that area.
This is not financial advice and as always, do your own research.
Happy Trading,
BBT
For $5 a month you can get access to my personal strategy, scanner, and private trade set-ups for traditional markets and crypto. Feel free to DM me for details.
Maybe tap 200 and fall back down?Would look to add on that trendline, could get explosive above 200 IMO
$VRTX BOFA initiates Vertex with BUY and $220 target.Entry level $179 = Target price $190 = Stop loss $174
Momentum and RSi are extremely strong.
Above $178 bullish trade entry having cleared MA resistance.
Earnings approaching, possible stimulant.
Vertex initiated at BofA/Merrill Vertex reinstated with a Buy at BofA/Merrill. BofA/Merrill analyst Geoff Meacham reinstated coverage of Vertex with a Buy rating and $220 price target, citing the company's differentiated growth profile, upside potential in the upcoming triple combination therapy launch, and an emerging orphan disease pipeline.
thefly.com
Vertex’s shares have lost 0.6% over the past three months compared with the Zacks Biomedical and Genetics industry’s decline of 4.7%. The Zacks analyst believes that Vertex’s third cystic fibrosis (CF) medicine, Symdeko, in a very short time, has become the main driver of its CF revenues.
Vertex rapidly advanced its triple combination CF regimen through late-stage development and regulatory filings. The regimen is crucial for long-term growth as it has the potential to treat up to 90% of CF patients. Meanwhile, Vertex’s non-CF pipeline, though early stage, looks interesting with several pipeline readouts expected in 2020-21.
However, competitive pressure is rising in the CF market with many other companies developing triple combo CF drugs. Also, Vertex’s dependence on just the CF franchise for growth is a concern. Shares have outperformed the industry this year so far. Estimates have gone up slightly ahead of Q3 earnings. Vertex has a positive record of earnings surprises in the recent quarters.
Source ZACKS.com
$VRTX High call buying with 25% potential gain by MAY 24thThis is not a name we are overly familiar with but in the past few weeks, we have noticed numerous upgrades and some large funds increasing exposure in the name. Finally higher than normal option activity was spotted on Friday with a significant upside return on the strike price. Like all Pharma stocks good news can be very good for the stock price, so keep watch.
VERTEX PHARMACEUTICALS INC.
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis
Vertex Pharma $VRTX weekly cup & handle in rising channelA favorite large cap Biotech into 2019 setting up for potential upside continuation
***PERFECT SHORT SETUP***NASDAQ:VRTX Sell short below yesterday's low. see my notes on the chart.
Please like, comment and follow if you like my ideas. THANK YOU!!!
Please note that this information is not a recommendation to buy or sell. It is to be used for educational purposes only.
$VRTX Overbought - Shooting Star Confirmed$VRTX Overbought - beginning to retrace today closing well below yesterday's low, confirming bearish shooting star reversal candle from yesterday. Will be looking for additional 8-10% downside from today's close to the area of the 200d ema near term. (More downside possible depending on outcome of Feb ER)
Target: $170-$175 range by mid February
Also of note, in fundamental news...Vertex just announced today they have terminated their COO/interim CFO as "the result of personal behavior that violated Vertex's Code of Conduct and values" - possibly more fuel to power this latest downward move. Expect a gap down at the open tomorrow morning.
Note: Informational analysis, not investment advice.
